文献速递肝病

血清胆汁酸谱与双胞胎中非酒精性脂肪性肝病的存在相关,且在活检证实的非酒精性脂肪性肝病患者中随纤维化分期增加呈剂量依赖性变化

Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
PubMed 文献 · Aliment Pharmacol Ther · 2018-12-02

该研究对两个队列(双胞胎与家族队列156人、活检证实的非酒精性脂肪性肝病队列156人)进行横断面分析,采用液相色谱/质谱检测空腹血清胆汁酸谱。结果发现非酒精性脂肪性肝病与非酒精性脂肪性肝病对照组之间总胆汁酸无显著差异,但胆汁酸谱随肝纤维化分期增加而显著改变。

要点

  • 在双胞胎与家族队列中,非酒精性脂肪性肝病组鹅脱氧胆酰结合物比例高于对照组(9.0% vs 6.5%,P=0.019),甘氨猪胆酸比例低于对照组(1.2% vs 3.6%,P<0.001)。
  • 在活检证实的非酒精性脂肪性肝病队列中,非酒精性脂肪性肝炎与非酒精性脂肪肝之间总胆汁酸无差异,但总非结合胆汁酸随非酒精性脂肪性肝炎分类显著下降(P=0.044)。
  • 总血清胆汁酸随纤维化分期增加而升高(P<0.001),初级结合胆汁酸比例增加(P<0.001),非结合胆汁酸(P=0.006)、非结合胆酰(P<0.001)和鹅脱氧胆酰结合物(P<0.002)随纤维化分期增加而显著下降。

核心结论

  • 空腹血清胆汁酸谱改变可见于非酒精性脂肪性肝病整个疾病谱。
  • 总血清胆汁酸在非酒精性脂肪性肝病与非酒精性脂肪性肝病对照组之间、以及非酒精性脂肪肝与非酒精性脂肪性肝炎之间无显著差异,但随着肝纤维化增加而显著扰动。

研究设计与样本

  • 横断面分析,包括一个156人的双胞胎与家族队列和一个156人的活检证实的非酒精性脂肪性肝病队列,采用液相色谱/质谱进行空腹胆汁酸谱检测。

主要发现

  • 在双胞胎与家族队列中(平均年龄46.3岁,体重指数26.6 kg/m2),36人(23%)患有非酒精性脂肪性肝病(磁共振成像质子密度脂肪分数≥5%)。
  • 非酒精性脂肪性肝病组鹅脱氧胆酰结合物比例高于非酒精性脂肪性肝病对照组(9.0% vs 6.5%,P=0.019),甘氨猪胆酸比例低于对照组(1.2% vs 3.6%,P<0.001)。
  • 在活检证实的非酒精性脂肪性肝病队列中(平均年龄49.8岁,体重指数32.0 kg/m2),非酒精性脂肪性肝炎与非酒精性脂肪肝之间总胆汁酸无差异。
  • 总非结合胆汁酸随非酒精性脂肪性肝炎分类显著下降(P=0.044)。
  • 纤维化分期分布为F0: 42.3%,F1: 32.7%,F2: 10.3%,F3: 8.3%,F4: 6.4%;总血清胆汁酸随纤维化分期增加而升高(P<0.001)。

关键数值与推荐

  • 总血清胆汁酸随纤维化分期增加而升高(P<0.001)。
  • 初级结合胆汁酸比例随肝纤维化分期增加而增加(P<0.001)。
  • 非结合胆汁酸(P=0.006)、非结合胆酰(P<0.001)和鹅脱氧胆酰结合物(P<0.002)随肝纤维化分期增加而显著下降。
  • 在双胞胎与家族队列中,非酒精性脂肪性肝病组鹅脱氧胆酰结合物为9.0%,非酒精性脂肪性肝病对照组为6.5%(P=0.019)。
  • 在双胞胎与家族队列中,非酒精性脂肪性肝病组甘氨猪胆酸为1.2%,非酒精性脂肪性肝病对照组为3.6%(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The fasting-state serum bile acid profile in nonalcoholic fatty liver disease (NAFLD) has been reported to differ when nonalcoholic steatohepatitis is compared to nonalcoholic fatty liver. However, there are few data comparing changes in NAFLD vs non-NAFLD, or whether the bile acid profile differs according to the degree of fibrosis. AIM: To examine the serum bile acid profile across the entire spectrum of NAFLD. METHODS: We performed a cross-sectional analysis of two complementary cohorts: a Twin and Family cohort of 156 participants, and a biopsy-proven-NAFLD cohort of 156 participants with fasting bile acid profiling using liquid chromatography/mass spectrometry. RESULTS: In the Twin and Family cohort (mean age 46.3 years and body mass index (BMI) 26.6 kg/m2 ), 36 (23%) participants had NAFLD (magnetic resonance imaging proton density fat fraction ≥ 5%). Higher chenodeoxycholyl conjugates (9.0% vs 6.5%, P = 0.019) and lower glycohyocholate (1.2% vs 3.6%, P < 0.001) were observed in NAFLD compared to non-NAFLD-controls. In the biopsy-proven-NAFLD cohort (mean age 49.8 years, BMI 32.0 kg/m2 ), no differences in total bile acid were seen between nonalcoholic fatty liver vs nonalcoholic steatohepatitis. The total unconjugated bile acid significantly decreased across nonalcoholic steatohepatitis categories (P = 0.044). The distribution of stage of fibrosis was F0: 42.3%, F1: 32.7%, F2: 10.3%, F3: 8.3% and F4: 6.4%. The total serum bile acid increased with increase in fibrosis stage (P < 0.001). The primary conjugated bile acid proportion increased (P < 0.001) whereas unconjugated bile acid (P = 0.006), unconjugated cholyl (P < 0.001) and chenodeoxycholyl conjugates (P < 0.002) significantly decreased with increase in liver fibrosis stage. CONCLUSIONS: Fasting-state serum bile acid profile alterations are seen across the entire spectrum of NAFLD. The total serum bile acids did not differ significantly between NAFLD vs non-NAFLD and nonalcoholic fatty liver vs nonalcoholic steatohepatitis, but were significantly perturbed progressively as liver fibrosis increases.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Caussy C, Hsu C, Singh S, et al. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther. 2018. PMID: 30506692. doi:10.1111/apt.15035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。